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ORIGINAL ARTICLE
Thymus-Derived Mesenchymal Stem Cells for Tissue
Engineering Clinical-Grade Cardiovascular Grafts
Dominga Iacobazzi, PhD,{ Megan M. Swim, PhD,{ Ambra Albertario, PhD,
Massimo Caputo, MD,{ and Mohamed T. Ghorbel, PhD{
Mesenchymal stem cells (MSCs) are attractive tools for regenerative medicine because of their multi-
differentiation potential and immunomodulation capacity. In congenital heart defect surgical correction,
replacement grafts lacking growth potential are commonly used. Tissue engineering promises to overcome
the limitations of these grafts. In this study, we hypothesized that human thymus-derived MSCs are a suitable
tool to tissue engineer a living vascular graft with good integration and patency once implanted in vivo.
Human thymus-derived MSCs (hT-MSCs) were identified by the expression of MSC markers and mesen-
chymal differentiation potential. When cultured onto natural scaffold to produce tissue-engineered graft, hT-
MSCs exhibited great proliferation potential and the ability to secrete their own extracellular matrix. In
addition, when implanted in vivo in a piglet model of left pulmonary grafting, the engineered graft exhibited
good integration within the host tissue, indicating potential suitability for corrective cardiovascular surgery.
The optimized xeno-free, good manufacturing practices-compliant culture system proved to be optimum for
large-scale expansion of hT-MSCs and production of tissue-engineered cardiovascular grafts, without com-
promising the quality of cells. This study demonstrated the feasibility of engineering clinical-grade living
autologous replacement grafts using hT-MSCs and proved the compatibility of these grafts for in vivo im-
plantation in a left pulmonary artery position.
Keywords: tissue engineering, mesenchymal stem cells, GMP grade, thymus, heart, corrective surgery,
congenital heart defect
Introduction
Following birth, stem cells reside in tissues for main-tenance and repair throughout an individual’s lifetime.1
Among these stem cells are a specific lineage known as
mesenchymal stem cells (MSCs). Phenotypic and genetic
evidence suggest that MSCs are immature cell types and
are able to retain their multilineage differentiation po-
tential in vitro until stimulated to the desired phenotype.2
To be defined as MSCs, progenitor cells must meet three
main criteria: (1) adherence to plastic, (2) specific cell an-
tigen expression, and (3) multipotent differentiation poten-
tial to the three main mesenchymal lineages, osteoblasts,
adipocytes, and chondroblasts.3 Most frequently isolated
from bone marrow, adipose tissue, and umbilical cord blood,
MSCs can also be isolated from a variety of different tissues
such as liver, spleen, pancreas, lung, kidney, aorta, vena
cava, brain, and muscle.3
The perivascular site of the tissue in which they reside has
been suggested as the MSC niche.4 It has also been hy-
pothesized a developmental affiliation between perivascular
cells, referred to as pericytes, and MSCs, given that the four
surface molecules commonly used as MSC markers CD44,
CD73, CD90, and CD105, are natively expressed by peri-
cytes.5 In particular, Caplan and colleagues have identified
pericytes as the source of MSCs, and this easily explains the
phenotypical and functional affinity, as well as the same
perivascular localization, between the two cell types. In this
light, it is a safe assumption to look at MSCs as pericytes;
however, all pericytes cannot be regarded as MSCs.6
Although cultured pericytes display the same functional
behavior of MSCs in vitro, recent findings have shown that
endogenous pericytes do not exhibit the same plasticity and
multilineage capacity as MSCs in vivo.7 Nonetheless, although
acting asmultipotent progenitor stemcells, themajor function of
MSCs in vivo has been assigned to their capacity to help restore
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and regenerate tissues at the site of injury.8 Therefore, the
perivascular origin of MSCs would adequately justify their role
in tissue repair, given that the anatomical locationmust allow the
cells to reach the wounded tissues and organs.
By holding a significant potential in tissue healing and
regeneration, supplemental MSCs, either from autologous or
allogenic sources, can be provided to help coordinate the
tissue regeneration and recovery in a wide range of clinical
conditions. In both preclinical and clinical settings, MSCs
from different sources have been explored to treat various
afflictions, including bone and cartilage diseases,9–11 graft-
versus-host disease,12 cardiovascular disease,13–15 liver dis-
ease,16,17 or diabetes mellitus.18
Few articles have suggested the neonatal thymus as an-
other potential source of MSCs.19 The thymus is a central
lymphoid organ that is located just above the heart in the
upper anterior thorax and is responsible for the maturation
of T cells.20 Reaching its greatest size by the end of the first
year of life, the thymus then undergoes involution that
continues over the course of an individual’s life, becoming
largely adipose tissue by the age of 50.21,22 Its location in
neonates, however, means that patients with congenital heart
defects (CHD) need a thymectomy before most surgical
heart repair. Normally discarded as waste, this tissue is
available for cell isolation without needing a donor or taking
bone marrow from an already ill child.23
The first description of human thymus-derived MSCs
(hT-MSCs) was their characterization by differentiation to
the three main mesenchymal lineages, as well as to myo-
blasts.24 Their multilineage potential has also been demon-
strated by the capacity to differentiate to neural-like cells25
and cardiomyocytes.26 hT-MSCs have been traced in vivo to
the interlobular trabeculae of the thymus.19 One of the main
benefits of thymus MSCs is their immune response regula-
tory ability, thanks to its pivotal role in immune system
development and function.27 When thymus MSCs were
cocultured with blood-derived T lymphocytes, the MSCs
significantly inhibited the proliferation of the T lympho-
cytes, thus demonstrating their immune regulation.27
Along with these unique therapeutic properties, their ease
of accessibility and expansion from discarded thymuses
during pediatric open-heart surgeries suggests that hT-MSCs
may be a useful therapeutic tool for the treatment of children
born with CHD.
Current treatment for CHD by corrective surgery revolves
around the use of prosthetic replacement grafts. Graft op-
tions currently used include prostheses such as Gore-Tex,
allografts, homografts, and xenografts, which are usually
porcine or bovine.28,29 However, these grafts have limited
durability and often require repeat operations because of the
lack of growth potential.30,31
Tissue engineering (TE) has emerged as a novel and
promising approach to overcome the limitation of current
treatments. By combining the use of autologous MSCs and
biocompatible scaffolds, TE promises to create autologous
cardiovascular grafts that could potentially remodel, repair,
and grow alongside the children’s growth. Most of the current
protocols for MSC expansion and TE involve the use of
animal-derived serum, growth factors, and enzymes for cell
isolation and expansion. One of the main challenges for the
clinical translation of cell-based tissue engineering therapy is
to replace the animal-derived components used for cell iso-
lation and expansion with products to eliminate the risk of
graft rejection, immune reactions, and viral or bacterial in-
fections.32,33 Furthermore, it is compulsory that all the com-
ponents used throughout the engineering of the graft, as well
as the technical procedures, are made according to good
manufacturing practices (GMP), to ensure optimal and safest
quality in tissue transplantation.34,35
In this study, we hypothesized that human thymus-
derived MSCs are a suitable tool to tissue engineer a living
vascular graft with good patency and integration upon
in vivo implantation. We have first purified, characterized,
and successfully in vitro expanded multipotent MSCs from
hT-MSCs. In addition, we have optimized the hT-MSC
culture and growth onto a naturally occurring scaffold
(CorMatrix), on which cells retained their stemness status
that is important for the paracrine signals to the surrounding
environment and for tissue regeneration. We demonstrated
that the produced living tissue provided a good engraftment
and lumen endothelialization upon in vivo implantation into
a large animal model. Furthermore, we have eliminated the
use of animal-derived components from isolation through-
out the production of the tissue-engineered vascular graft.
To the best of our knowledge, this is the first study com-
paring the biological and functional properties of hT-MSCs
and hT-MSC-derived tissue-engineered vascular graft, cul-
tured in standard and GMP culture systems. The capacity of
human thymus-derived MSCs to grow in an animal-free and
GMP-compliant environment is an important step for the
clinical translation of our hT-MSC TE approach. This study
represents the proof of concept that it is possible to produce
clinical-grade cardiovascular grafts capable of in vivo inte-
gration for congenital heart disease corrective surgery.
Materials and Methods
Ethics
Human tissue was collected from patients undergoing
congenital heart surgery in compliance with the Human
Tissue Act. Perinatal and leftover material (the thymus) was
taken with parents’ consent under NHS ethics license (REC
ref. 06/Q2001/197 and 11/SW/0122).
Isolation and culture of thymus MSCs
Thymus tissue (n = 6) was collected in sterile phosphate-
buffered saline (PBS) from the surgical theater. The thymus
was washed in PBS (Life Technologies) and fat and blood
were dissected off. Tissue was minced into small pieces
(*1mm3), followed by collagenase I (0.3mg/mL; Sigma-
Aldrich) enzymatic digestion at 37C for 2 h. The digested
tissue was poured into a 70-mm cell strainer (Falcon) and
forced through the strainer using the plunger of a 10mL sy-
ringe (BD). The strainer was continually washed with fresh
medium. The resulting cell suspension was centrifuged for
5min at 1500 rpm at 22C. The supernatant was discarded
and cells were resuspended in Dulbecco’s modified Eagle
medium, low glucose (DMEM; Life Technologies) with 10%
HyClone fetal bovine serum (FBS; Thermo Scientific), 1%
penicillin/streptomycin (P/S; Life Technologies), and basic
fibroblast growth factor (FGF, 2.5 ng/mL; Peprotech) on un-
coated plastic, at *1· 106 cells/cm2 density. The resulting
passage (P0) cultures were kept at 37C in a humidified
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atmosphere with 5% CO2. After 72–96 h, nonadherent cells
were removed with two PBS washes. Adherent cells were
cultured until confluence was reached, with feeding every 48–
72h. At this point, cells were detached using Trypsin-EDTA
(0.05%; Life Technologies) and then plated at*1· 104 cells/
cm2 in new flasks for next passage (P1).
Isolation and culture of thymus MSCs
under GMP conditions
Thymus tissue was collected in sterile PBS from the surgical
theater. For comparison studies, the same thymus was cut in
two and GMP conditions were compared directly to standard
conditions. It was then cleaned and minced in GMP quality
Dulbecco’s PBS (GMP PBS; Sigma-Aldrich) and enzymati-
cally digested for a 2-h incubation with collagenase NB6 GMP
(0.3mg/mL; Serva) at 37C. The tissue was passed through a
70-mm cell strainer, which was washed with fresh GMP PBS.
Cell suspension was centrifuged at 1500 rpm at 22C for 5min.
The supernatant was discarded and cells were resuspended in
CTS StemPro MSC SFM DMEM (GMP DMEM; Life
Technologies) with 10% Human Platelet Lysate (hPl;
MACO Biotech) and recombinant human FGF (2.5 ng/mL;
Peprotech), and were plated on uncoated plastic. The result-
ing passage (P0) cultures were kept at 37C in a humidified
atmosphere with 5% CO2. After 72–96 h, nonadherent cells
were removed with two washes with GMP PBS. Adherent
cells were cultured in GMP DMEM, 10% hPl, and FGF with
medium changes occurring every 48–72 h and then split
when confluence was reached. When confluence was
reached, cells were removed from plastic by washing once
with GMP PBS, followed by incubation with Trypsin-
EDTA (0.05%; Roche), and were then plated at *1 · 104
cells/cm2 in new flasks for the next passage (P1).
FACS
Fluorescent-activated cell sorting analysis (FACS) was used
to determine cell surface and intracellular cell marker expres-
sion. All centrifugations refer to the same conditions of
1500 rpm at 22C for 5min. Cells were removed from plastic
with trypsin, resuspended in cold FACS Buffer (2% FBS in
PBS), and centrifuged. Cells were resuspended in FACS buffer
and counted. A minimum of 100,000 cells were removed for
unstained control and a minimum of 200,000 cells were re-
moved for live/dead control. Half the live/dead control cells
were put on 95C hot block for 5min, to instigate cell death,
and then cooled in the fridge. Remaining cells were stained
with a viability marker (V450, Table 1) for 30min at 4C, then
washed with cold FACS buffer and centrifuged. Supernatant
was discarded and cells were resuspended such that there was
100mL for each tube. Cell suspension was added to each tube
with antibodies (Table 1) and incubated at 4C for 30min in
the dark. During this incubation, cooled live and dead control
cells were pooled and stained with the viability marker. In
addition, three tubes of compensation beads (Comp Beads
Plus; BD Biosciences) were stained with a fluorescein iso-
thiocyanate (FITC), a phycoerythrin (PE), and an allophyco-
cyanin (APC) stain, respectively.
All tubes were washed once with cold FACS buffer and
centrifuged. All tubes (included unstained tube) were then
incubated with cytofix/cytoperm solution (BD Pharmingen) at
4C in the dark for 15min. Tubes were then washed once with
1· perm/wash solution (BD Pharmingen). Tubes that did not
require intracellular markers were resuspended in 300mL
FACS buffer and 100mL 4% paraformaldehyde (PFA) (Sigma-
Aldrich). Tubes with intracellular markers were resuspended in
100mL 1· perm/wash and intracellular antibody (Table 1) and
incubated in the dark at 4C for 30min. Tubes were then
washed once in 1· perm/wash, centrifuged, and resuspended
in 300mL of FACS buffer and 100mL 4% PFA, and stored
with remaining tubes until analysis. Tubes were analyzed on
a FACS Fortessa flow cytometer (BD Biosciences) using
FACSDiva (BD Biosciences) for data collection and FlowJo
(Treestar, Ashland) for analysis. Unstained cells, live/dead
controls, and compensation beads were used to set compen-
sation and create positive and negative gates.
In vitro multilineage differentiation
Multilineage differentiation into osteoblasts, adipocytes,
and chondrocytes was assessed by incubating the cells, at
passage between 3 and 5 (2000 cells/cm2), in alpha MEM
Table 1. Antibodies Used for FACS Staining
Antibody Company Color Dilution Catalog # Measures
CD105 R&D Systems PE 1:20 FAB10971P MSCs
CD90 R&D Systems PE 1:5 FAB2067P MSCs
CD45 R&D Systems PE 1:20 FAB1430P Leukocytes
CD31 BD Pharmingen FITC 1:20 560984 Endothelial cells
CD34 eBioscience FITC 1:40 11-0349-42 Hematopoietic stem cells
CD73 BD Pharmingen APC 1:50 560847 MSCs
CD13 BD Pharmingen APC 1:20 561698 MSCs
CD44 BD Pharmingen APC 1:20 560890 MSCs
CD40 BD Pharmingen APC 1:20 561848 Endothelial, epithelial cells
HLA-DR BD Pharmingen APC 1:20 560896 Human leukocytes
Fixable viability stain BD Horizon V450 1:1000 562247 Live/dead cells
CD166 BD Pharmingen PE 15:100 559263 Activated leukocyte adhesion molecule
CD79alpha BD Pharmingen APC 1:10 551134 B cells
CD29 BD Pharmingen APC 1:5 559883 Lymphocytes, monocytes, granulocytes
CD14 BD Pharmingen PE 1:10 555398 Monocytes and macrophages
MSC, mesenchymal stem cell.
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medium with specific StemXVivo supplement kits (R&D
system) for different timescales. Osteogenic differentiation
was assessed after 3 weeks of culture by Alizarin Red
(Sigma-Aldrich) detection of calcific deposition. Oil Red O
(Sigma-Aldrich) staining was used to detect lipidic accu-
mulation of cells undergoing 2 weeks of adipogenic differ-
entiation. Alcian blue (Sigma-Aldrich) staining was used to
determine chondrogenic cartilage formation after 3 weeks of
cell culture.
In vitro functional studies
All in vitro experiments assessing differences throughout
expansion were set up with cells at P1, P3, P5, P7, P9, and
P11 (P5 to P11 for senescence assay) under the same ex-
perimental settings.
For population doubling (PD) counts, cells were seeded at
initial cell density of 5000 cells/cm2 and kept in culture for
72 h. PD was calculated by using the following formula: log
(end cell/start cell)/log.2
CFU-F (colony-forming unit-fibroblast) assay was per-
formed by seeding cells at very low density (100 cells/cm2)
in a culture Petri dish. After 2 weeks, the dishes were stained
with 3% Crystal Violet (Sigma-Aldrich) and the number of
colonies was counted.
For proliferation assessment, the BrdU immunofluores-
cence assay (Roche) was used, according to the manufac-
turer’s instructions.
The b-galactosidase Senescence Detection kit (Calbio-
chem) was used as a biomarker of senescence in MSCs. The
percentage of senescent cells was represented by the number
of b-galactosidase-stained cells in total population.
All in vitro assays were performed in triplicate wells and
in six independent experiments.
Peripheral blood mononuclear cells proliferation assay
The immunosuppressive property of hT-MSCs was ana-
lyzed in coculture experiment with activated (10 mg/mL
Phytoaemoagglitinin; eBioscience) allogenic peripheral
blood mononuclear cells (PBMC). hT-MSCs in appropriate
medium, were treated with mitomycin C (Sigma-Aldrich),
50 mg/mL for 50min, to inactivate proliferation. Afterwards,
PBMCs were freshly isolated by density-gradient cen-
trifugation and were added to culture wells with or without
hT-MSCs (MSC-PBMC, 1:10 ratio). (Co-) Cultures were
maintained for 72 h, at which point BrdU labeling solution
was added and cell proliferation assessed after 6 h with the
fluorimetric immunoassay kit.
Multiplex analysis of cytokine production
Cytokine and growth factor production were analyzed in
supernatants of PBMC alone, hT-MSCs cultured under
standard and GMP conditions, and in coculture experiments
(MSC–PBMC, 1:10 ratio). After 72 h of cell culture, su-
pernatants were collected, concentrated, and analyzed using
a cytokine/chemokine multiplex kit (Millipore), composed
of beads for the detection of IL-2, IL-6, IL-8, INFg, TNFa,
and VEGF, according to the manufacturer’s instructions.
Analysis was performed using a Luminex MAGPIX in-
strument (Luminex Corporation).
Bioreactor
Cells were seeded on the surface of the CorMatrix scaffold
at 5· 105 cells/cm2 and were cultured under static conditions
in an appropriate medium for 1 week to allow cells to adhere.
The engineered graft was then stitched to the rotating arm of
a bioreactor (Harvard Apparatus) in a conduit-shape manner
with the cells facing the outer side of the scaffold. The ro-
tation was set at 0.5 rpm and slowly increased within 24 h to
the final speed of 2 rpm, which was kept for 1 week. After
the static and the static followed by dynamic culture, the
viability of the seeded cells was assessed by a fluorescent
viability/cytotoxicity assay (Life Technologies) according to
the manufacturer’s instruction. Seeded grafts were imaged
on a Zeiss Axio Observer.Z1 with Zen Blue software (Zeiss).
Mechanical testing of the engineered graft
Nonseeded and cell-seeded CorMatrix pieces were ana-
lyzed for mechanical properties using an Instron 3343B
machine (Instron, UK) with a 100N load cell and pneumatic
grips. Crosshead speed was 10mm/min. Samples were
measured for tensile stress at break using Bluehill software
(Instron, UK).
In vivo implantation of vascular grafts engineered
with pig-thymus MSCs
Three- to four-week-old female Landrace pigs of 10–15 kg
were employed in this study. Animals were treated in accor-
dance with the ‘‘Guide for the Care and Use of Laboratory
Animals’’ published by the National Institutes of Health in
1996 and conforming to the ‘‘Animals (Scientific Procedures)
Act’’ published in 1986. The CorMatrix was engineered with
pig thymus MSCs, whose isolation, characterization, and
graft engineering were performed following the same pro-
tocol used for the hT-MSCs. Surgical procedures were
performed under general anesthesia and neuromuscular
blockade. A left posterolateral thoracotomy was performed
and a conduit-shaped graft was inserted in the left pulmo-
nary artery. Animals were recovered with intense moni-
toring for the first 24 h during which period, analgesics and
antibiotics were administered according to the needs.
Animals were monitored with a two-dimensional Doppler
Echocardiography (VividQ; GE Healthcare) before the
surgery and after 1, 2, and 3 months to assess the graft
patency and blood flow. After 3 months of follow-up, pigs
were euthanized and pulmonary arteries were dissected from
the heart, and then fixed in 4% PFA or fresh-frozen in liquid
nitrogen.
Immunohistochemistry
For paraffin embedding, samples were fixed in 4% PFA,
washed in PBS, moved in to cassettes (Histosette I; Simport),
processed in a Thermo Excelsior AS, and embedded in a
Thermo HistoStar machine. A Sandon Finesse 325 (Thermo)
microtome was used to cut 5-mm sections, which were floated
onto Menzel-Glaser Superfrost Plus slides (Thermo). Slides
were stored at 37Covernight to dry completely before staining.
Staining with hematoxylin and eosin (H&E) and van Gieson’s
(EVG) were performed using a Shandon Varistain 24-4
(Thermo). Slides were removed from machine and mounted
with DPX (distyrene, a plasticizer, in toluene-xylene; Sigma-
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FIG. 1. Phenotypical and functional characterization of hT-MSCs at passage 2. (a) Representative histograms showing the
expression of typical MSC markers (CD105, CD 73, CD90, CD29, CD166, and CD44) and absence of hematopoietic and
endothelial markers (CD45, CD34, CD14, cd79a, HLA-DR, and CD31) by flow cytometry. (b) Bar graph illustrating the
average of six biological replicates (mean – SEM). (c) Multipotency property of hT-MSCs. Cells exhibit differentiation
potential after culture in adipogenic, osteogenic, and chondrogenic media. Oil Red O was used to visualize fat droplets after
adipogenic induction (i, iv), Alizarin red to stain osteogenic calcium-rich deposits (ii, v), and Alcian blue to identify chon-
drogenic cartilage formation (iii, vi). Results are from a single experiment representative of three independent experiments on
three separate patients’ hT-MSC samples. Scale bars = 50mm.MSC,mesenchymal stem cell; SEM, standard error of the mean.
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Aldrich) with 24· 50mm cover glass (VWR). Slides were
imaged on a Zeiss Axio Observer.Z1 with Zen Blue software
(Zeiss).
Statistical analysis
Data are expressed as mean –SEM. Samples were ana-
lyzed by Student’s t test or one-way analysis of variance
followed by Tukey’s HSD post hoc test. Results were con-
sidered significant if p £ 0.05.
Results
Human thymus contains functional mesenchymal
stem cells
After mechanical dissociation and collagenase I digestion
of the pediatric patient’s thymus, a cell population was
obtained. Observation by microscopy at day 2 of primary
culture showed that hT-MSCs adhered to the plastic surface
of culture dish and presented a fibroblast-like cell mor-
phology (Supplementary Fig. S1a, b; Supplementary Data
are available online at www.liebertpub.com/tea). These cells
proliferated rapidly in the expansion culture medium, ac-
quiring a more homogeneous morphology after passage 2
(Supplementary Fig. S1c, d). At this passage (P2), flow cy-
tometry analysis revealed that hT-MSCs exhibited the main
typical MSC surface markers (CD29, CD44, CD73, CD 90,
and CD 105) and were negative for hematopoietic (CD34),
monocyte (CD14), leukocyte (HLA-DR, CD45), B cell
(CD79alpha), and endothelial markers (CD31) (Fig. 1a, b).
To explore their functional characterization and differ-
entiation potential, cells at early passage (P2) were induced
to differentiate with osteogenic, adipogenic, or chondro-
genic supplements in the culture medium. The cells showed
a high degree of calcium deposition following osteogenic
differentiation as confirmed by Alizarin staining. Similarly,
adipogenic differentiation was estimated by positive stain-
ing of lipid vesicles using Oil Red O stain. Finally, sulfated
proteoglycans, visualized by Alcian Blue staining, proved
the chondrogenic differentiation of hT-MSCs (Fig. 1c).
Given that cells are often required to be passaged several
times to reach an adequate number for implantation, the
phenotypical and functional properties of hT-MSCs were
further evaluated in later passages. The typical MSC im-
munophenotype and multilineage differentiation capacity
were still retained at passage 5 (Supplementary Fig. S2a, b),
supporting the evidence that hT-MSCs do not lose their
unique properties throughout passages and can still stand as
an excellent tool for stem cell therapy and/or TE cardio-
vascular grafts at later passages.
hT-MSCs exhibit cell attachment and growth potential
onto CorMatrix scaffolds
To tissue engineer cardiovascular grafts for congenital
heart disease surgery and repair, it is crucial that cells adhere
and evenly proliferate onto a naturally occurring scaffold.
Therefore, we tested the capability of hT-MSCs to grow and
integrate into the CorMatrix, a decellularized porcine
small intestinal submucosa extracellular matrix (ECM)
(Fig. 2a). Viability and cytotoxic assay showed that MSCs,
grown for 2 weeks on the scaffold, were completely viable
and proliferative as demonstrated by the calcein positive
staining of the cells. A negligible number of dead cells was
detected, as suggested by the low amount of Ethidium dye,
incorporated by damaged cells (Fig. 2-i).
Histological analysis further confirms the even arrange-
ment of the cells on the seeded scaffold (Fig. 2-ii). In ad-
dition, the EVG staining revealed that MSCs were able to
synthesize their own ECM, as suggested by the positive
staining for the ECM components collagens and elastin
(Fig. 2-iii). An aligned, confluent cell layer could also be
detected on the CorMatrix surface by scanning electron
microscopy (Fig. 2-iv).
To overcome the limitations associated with traditional
static culture conditions, a bioreactor was used. This system
helps triggering biochemical and physical regulatory signals
within seeded cells, encouraging them to grow and produce
ECM to a greater extent.
The cell cultured under this dynamic system showed a greater
potential for MSC growth, as detected by the calcein staining
(Fig. 2-v). Furthermore, the dynamic culture allowed the cells to
arrange into a tightly packed multicell layer (Fig. 2-vi, viii) and
synthesize a higher amount of ECM components (Fig.-2 vii),
proving that a dynamic system is essential to improve the in vitro
development of the new tissues. This multicell layer maintained
its cell phenotype as demonstrated by the expression of theMSC
marker CD44 (Fig. 2c).
To determine the strength of the seeded scaffold, tensile
testing was carried out. CorMatrix seeded with MSCs and
FIG. 2. Biological and mechanical characterization of the engineered grafts. hT-MSC attachment, growth, and integration
into CorMatrix scaffold under standard and GMP conditions (a, b). (a) Analysis under standard conditions. (i, v) Viability/
Cytotoxicity Assay of hT-MSCs seeded on CorMatrix. Cells were left to grow in (i) static and (v) dynamic conditions.
Calcein AM and EthD-III fluorescent probes were used to detect, respectively, live (green fluorescence) and dead (red
fluorescence) cells. Scale bar = 100 mm. Histological sections and scanning electron microscopy (SEM) of hT-MSCs grown
CorMatrix. H&E staining of nuclei (black arrows) in (ii) static and (vi) dynamic conditions. EVG staining of elastin and
collagen deposition (black arrows) in (iii) static and (vii) dynamic conditions, respectively. Scale bar = 50mm. SEM
showing cells grown to confluence on surface of CorMatrix in (iv) static and (viii) dynamic conditions. Scale bar = 100mm
(b) Analysis under GMP conditions. (ix, xiii) Viability/Cytotoxicity Assay of GMP-cultured hT-MSCs on CorMatrix, in (ix)
static and (xiii) dynamic bioreactor. Scale bar = 100mm. (x, xiv) H&E and (xi, xv) EVG staining, and (xii, xvi) SEM
revealed that dynamic culture system showed a greater potential for cell growth and orientation into a multicell layer. 50mm
(x, xi, xiv, xv); Scale bars = 100mm (xii, xvi). (c) Immunostaining with the MSC marker CD44 (green) illustrates cells
seeded on the CorMatrix (bright field) retain their mesenchymal phenotype. Scale bar = 50mm. (d) Tensile strength and
stiffness of the engineered graft. Ultimate tensile strength and Young’s modulus were not significantly different between the
CorMatrix seeded with cells and kept in dynamic conditions compared to unseeded CorMatrix. GMP, good manufacturing
practices; H&E, hematoxylin and eosin; MPa, megapascal.
‰
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kept in culture for 1 week under static conditions and 1
week under dynamic conditions was compared to nonseeded
CorMatrix (Control). No significant difference in the ulti-
mate tensile strength was noted when comparing the two
groups (Fig. 2d). In addition, stiffness, as measured by
Young’s Modulus of elasticity, was not significantly dif-
ferent between the two groups (Fig. 2d).
Thymus MSC-engineered graft shows in vivo
integration and regeneration of the host vascular tissue
To assess the in vivo efficacy of the engineered vascular
graft produced in vitro, we have developed a large animal
model, in which the thymus MSC-engineered tissue was
grafted into the piglet left pulmonary artery. Our data
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collected 3 months after in vivo implantation revealed that
the graft was patent with no stenosis, rupture, or defor-
mation. Macroscopic observation of the MSC-seeded graft
harvested at 3 months showed smooth luminal surfaces
without signs of thrombosis and tissue degradation
(Fig. 3a, b). Histological analysis of the explanted tissue
showed that the graft exhibited an extensive nucleation
throughout its structure (Fig. 3c, d).
In addition, the immunohistochemical analysis showed an
organized multilayer of smooth muscle cells populating the
tunica media (Fig. 3e, f). Furthermore, immunohistochem-
ical and electron scanning microscopy showed a newly
formed layer of endothelial cells in the luminal side of the
graft (Fig. 3e, f, h, i). Finally, the observation of new vessels
in the adventitia provides a good indication of neovascu-
larization, which is important for oxygenation and nutrient
supply within the graft (Fig. 3g).
hT-MSCs retain phenotype and differentiation
properties after culture under GMP conditions
After proving that the human thymus, surgically removed
during neonatal cardiac repair, can be an excellent source of
MSCs, we next optimized a xeno-free culture system,
compliant with GMP standard.
Phenotypic analysis of hT-MSCs cultured under GMP-
compliant conditions revealed that cells retained the typical
MSC markers throughout passages (P2–P5) and absence of
immune, hematopoietic, and endothelial markers (Fig. 4a and
Supplementary Fig. S3a). In addition, the differentiation
FIG. 3. In vivo explanta-
tion of CorMatrix seeded
with thymus MSCs. (a, b)
Macroscopic images show-
ing the cut-open left pulmo-
nary artery. The graft has
similar macroscopic mor-
phology to surrounding na-
tive pulmonary artery (PA)
tissue. (c, d) H&E staining of
the native pulmonary artery
compared to explanted graft.
The graft H&E has extensive
nucleation. (e–g) Im-
munohistochemistry of the
native pulmonary artery
compared to explanted graft.
Smooth muscle actin (red)
staining and isolectin stain-
ing (green) illustrate a multi-
smooth muscle cell layer and
a luminal endothelial cell
layer in native tissue (e) and
graft (f). (g) The adventitia
shows vascularization. Scan-
ning electron micrographs of
the luminal surface shows the
topography of endothelial
cell layer in the native tissue
(h) and the graft (i).
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capacity was conserved, after culture in adipogenic-, osteo-
genic-, and chondrogenic-supplemented media both at earlier
and later passages (Fig. 4b and Supplementary Fig. S3b).
hT-MSCs cultured under GMP conditions exhibit
better functional behavior compared to standard
cultured conditions
Functional features were next assessed to determine whe-
ther the GMP-optimized culture conditions affected cell
growth and viability. Therefore, a battery of in vitro assays was
performed to address differences in growth potential, by ana-
lyzing proliferation and senescence throughout the expansion.
BrdU incorporation revealed a significantly higher level
of proliferation activity when MSCs were cultured under
GMP media (observed at P5). For both culture conditions, a
trend toward decreased proliferation was seen at later pas-
sages, although not statistically significant (Fig. 5a).
The clonogenic capacity and growth kinetics were also
evaluated. The CFU assay and PD were, respectively,
comparable between the standard and GMP condition at
early passages (Fig. 5b, c). It may be worth noting that
GMP-cultured cells exhibited a trend toward higher number
of colony and more PD at higher passages, although not
statistically significant. The incidence of cell senescence
was lower in GMP-cultured MSCs, as suggested by the
lower activity of the b-galactoside enzyme (Fig. 5d, e).
Taken together, these data prove that hT-MSC behavior is
not affected, but rather improved, by the change of culture
condition, from standard to a GMP-optimized system.
hT-MSCs cultured under standard and GMP conditions
display comparable levels of protein secretion
and immunosuppressive capacity
Proteins secretion was also compared by analyzing the
secretome of hT-MSCs cultured under standard and GMP
conditions. Inflammatory cytokines, such as IFNg, IL-2, and
TNFa, were expressed at very low levels in both media,
while the immunomodulatory IL-6 and the angiogenic factor
VEGF were secreted in higher amount. However, no sig-
nificant differences were detected between the two media.
Interestingly, only the chemokine IL-8 was found to be
significantly higher in the secretome of GMP-cultured hT-
MSCs (Fig. 6a).
Immunosuppressive capacity of the cells cultured in both
conditions was tested by evaluating the ability to suppress al-
logenic PBMC proliferation. When cocultured with hT-MSCs,
activated PBMC significantly reduced their proliferation rate
(Fig. 6b). In addition, the secretion of immunomodulatory
cytokine by PBMC was also significantly decreased with
cocultured hT-MSCs under both standard and GMP condi-
tions, further demonstrating that hT-MSC-immunosuppressive
capacity was maintained when cultured under both standard
and GMP conditions (Fig. 6c).
hT-MSCs growth potential on CorMatrix is retained
under static and dynamic GMP culture conditions
Finally, the growth potential of MSCs cultured on the
CorMatrix scaffold, in GMP conditions was assessed
FIG. 4. Phenotypical and func-
tional analysis of hT-MSCs cul-
tured under standard (non-GMP)
and GMP-compliant conditions. (a)
FACS analysis reveals comparable
expression of typical MSC markers
and absence of hematopoietic and
endothelial markers in hT-MSCs
cultured under standard and GMP
conditions at passage 5. (b) Multi-
potency evaluation of hT-MSCs
cultured under GMP-compliant
conditions at passage 5. hT-MSCs
retain differentiation potential after
culture in (i, iv) adipogenic (Oil
Red O staining), (ii, v) osteogenic
(Alizarin staining), and (iii, vi)
chondrogenic (Alcian Blue) induc-
ing media. Scale bars = 50mm.
ENGINEERING GMP-GRADE GRAFTS USING THYMUS MSCS 9
D
ow
nl
oa
de
d 
by
 U
ni
ve
rs
ity
 o
f B
ris
to
l f
ro
m
 o
nl
in
e.
lie
be
rtp
ub
.c
om
 a
t 0
2/
06
/1
8.
 F
or
 p
er
so
na
l u
se
 o
nl
y.
 
(Fig. 2b). Viability/cytotoxicity assay and histological
analysis of the seeded scaffolds were carried out under this
growth condition. A large amount of viable cells, detected
by calcein incorporation, was observed when cells were
cultured under the static and, to a higher extent, under the
dynamic system provided in the bioreactor (Fig. 2-ix, xiii).
As seen for the MSCs grown under a standard culture
condition (Fig. 2a), the bioreactor proved to be a crucial
factor in helping the cell growth and synthesis of ECM, as
the H&E staining of nuclei and EVG staining of collagen
and elastin showed (Fig. 2-x, xiv, xi, xv).
Furthermore, images from scanning electron microscopy
showed a greater potential for cell growth and orientation
into a multicell layer under a dynamic culture system
compared to static conditions (Fig. 2-xii, xvi). This finding
represents an important step toward the clinical-grade
FIG. 5. In vitro functional assessments during hT-MSC expansion. (a–c) Growth potential analyzed by (a) BrdU in-
corporation, (b) colony-forming unit, and (c) population doubling revealed a comparable or even better performance of hT-
MSCs cultured under GMP conditions, compared to standard, non-GMP, conditions. (d, e) Incidence of senescence,
measured by (d) b-galactosidase activity, was lower in GMP-cultured MSCs. (e) Representative images of b-galactosidase-
positive cells (green stain). Scale bar = 100 mm; nuclei counter stain (DAPI) was used for cell count normalization. Data are
expressed as mean—SEM of six experiments. *p < 0.05 versus control.
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realization of an engineered cardiovascular graft using
MSCs derived from human thymus tissues.
Discussion
MSCs have gained significant attention in the last decades.
The easy accessibility and versatile biological properties, due
to their high proliferative capacity and multilineage differ-
entiation potential, have suggested that MSCs may represent
a useful therapeutic tool for various disorders.36 To the best
of our knowledge, this report represents the first study of
a systematic and extensive culture of MSCs derived from
human thymus and their use in the production of tissue-
engineered grafts for CHD repair.
Although previously suggested as a potential source of
MSCs, the thymus has little been regarded as a potential tool
for regenerative medicine, due to the invasive procedure of
its removal. However, a thymectomy is often necessary for
surgical access in the correction of many CHD, the most
common birth defect worldwide.23 Hence, this normally
discarded tissue can become a precious source of autologous
stem cells to be used in the correction of the child’s defect.
The thymus-derived MSCs we have isolated, homoge-
neously expressed the typical marker and multilineage dif-
ferentiation capacity of MSCs throughout passages. This is
crucial, given that MSCs to be used for CHD require an
intensive cell culture and propagation. In fact, unlike other
cardiovascular repair, such as myocardial infarction or
FIG. 6. Analysis of protein se-
cretion and immunosuppressive
capacity of hT-MSCs. (a) Graphs
showing the quantification of cy-
tokines, growth factors, and che-
mokines (pg/3 · 105 cells) released
by hT-MSCs cultured under stan-
dard and GMP conditions. (b)
BrdU incorporation assay showing
a reduction of the proliferation of
activated PBMC in coculture with
MSCs under standard and GMP
conditions. (c) Quantification of
immunomodulatory factors re-
leased by PBMC alone and in co-
culture with hT-MSCs. Upon
coculture of MSCs with activated
PBMC, lower amount of immuno-
modulatory proteins could be de-
tected in PBMC supernatants,
compared to PBMC culture alone.
Data are expressed as mean—SEM
of four or five experiments
(*p < 0.05; **p< 0.005). PBMC,
peripheral blood mononuclear cell.
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cardiomyopathy where the use of MSCs have been exten-
sively investigated,13,37 in CHD, some anatomic structures
of the heart are usually absent or highly compromised and
MSCs cannot simply be injected to the defective site.
Therefore, a surgical correction to introduce or replace the
compromised structure is the only treatment.
The current cardiovascular grafts used for corrective heart
surgery did not prove to be effective for the long-term repair,
due to limited durability and patency and recurrent calcifi-
cation episodes.28,38,39 TE, by combining autologous MSCs
and biocompatible scaffolds, potentially offers the solution
to this limitation. The production of tissue-engineered con-
structs requires an extensive cell culture process and an
optimal environment for the growth of the graft. Our thymus-
derived MSCs showed a high proliferation rate during ex-
pansion, which was retained when cells were cultured onto
different biological scaffolds (unpublished data).
For the potential clinical translation of this work, we
have focused on the commercially available CorMatrix, a
decellularized porcine small intestinal submucosa, currently
in use in cardiac reconstruction procedures. Unlike other
materials used in cardiac defect corrective surgery, the
CorMatrix holds the advantage of avoiding the immune
response associated with xenograft and homograft materi-
als.40–42 In addition, as a decellularized biological scaffold,
it possesses the potential for the accommodation and growth
of host cells, which is an essential feature in TE. For this
reason, and for being a scaffold already approved by the
Federal Drug Administration (FDA) for use in cardiovas-
cular repair, we have chosen the CorMatix as the most
suitable scaffold for the realization of the MSC-engineered
graft and the potential clinical translation of this work.
Clinical data about CorMatrix used in routine congenital
heart surgical repair have shown, so far, favorable outcomes;
however, long-term follow-up are missing.43,44 Woo et al.
have histologically examined CorMatrix materials explanted
from pediatric patients undergoing open heart surgeries. De-
spite an overall favorable clinical outcome for patients, the
explanted specimens showed a high degree of fibrosis and
chronic inflammation, with no patch recellularization or in-
tegration within the surrounding tissue.45 The in vitro re-
population of decellularized patches has proved to provide a
significantly higher integration, regeneration, and function of
the tissue when implanted in animal models.46,47 Investiga-
tions are currently being conducted to identify the ideal hu-
man cell types for use in cardiovascular TE.
The finding that our isolated and characterized hT-MSCs
can sustain growth and proliferation on the CorMatrix
makes them a favorable candidate for TE cardiovascular
grafts for CHD. In addition, our study provides an in vivo
proof of concept that our engineered graft can be safely used
in a left pulmonary artery position.
For this animal-based preclinical study, we have used a
porcine model, whose cardiovascular system more closely
resembles the anatomy and function of a human counter-
part.48 In addition, such large animal model has the ad-
vantage of a longer life span and a rapid growth speed,
which facilitate longitudinal studies critical for stem cells
and TE applications. Besides proving the safety of our en-
gineered graft, the piglet model allowed us to optimize the
size and shape of the scaffold and develop a surgical pro-
cedure suitable for clinical application.
The surgical technique developed by our group, which
consists of the reconstruction of the left pulmonary artery,
can serve as a suitable model for some complex CHD such
as pulmonary atresia or truncus arteriosus, where the pul-
monary artery has to be reconnected to the right ventricle
with a conduit. Our study demonstrates the capacity of
the hT-MSC tissue-engineered conduit to effectively engraft
in the host pulmonary artery. Furthermore, 3 months after
implantation, the MSC-engineered graft exhibited a good
integration within the host-surrounding site, with no evi-
dence of thrombosis, occlusion, or stenosis.
In addition to the structural support to the graft, the pres-
ence of MSCs on the scaffold can be beneficial in provid-
ing the microenvironment for local tissue regeneration. It
has become clear that MSCs exhibit both a trophic and
immunomodulatory activity, which drive the vascular cell
recruitment and the reduction of immune response, respec-
tively.8 By conducting a multiplex analysis of cytokine and
chemokine production, we found that hT-MSCs release a
high amount of VEGF, IL-6, and IL-8, compared to other
factors. VEGF is a recognized chemotactic factor for en-
dothelial cells.49,50 In addition, it has been demonstrated
that it can exert an indirect immunosuppressive effect by
increasing the secretion of indoleamine 2,3-dioxygenase, a
negative regulator of immune response, by dendritic cells,
thus affecting lymphocyte proliferation and activation.51 IL-
8 has also been shown to exhibit proangiogenic effect by
promoting endothelial cell proliferation and migration.52
In this study, electron microscopy and immunocyto-
chemistry analysis of the explanted graft indicated the
building of a layer of endothelial cells on the luminal side of
the graft. Furthermore, a consistent amount of cell growth is
also evident in the tunica media and the adventitia, where
vessel-like structures could be observed, providing the evi-
dence of a neovascularization occurring in the graft. How-
ever, a longer term follow-up may be needed to observe a
complete cell repopulation identical to the structure of the
native pulmonary artery.
Among the soluble factors released in the conditioned
medium, a great amount of IL-6 was also detected. Despite its
well-established role as an immune-suppressive factor, recent
evidences have pointed to IL-6 as an anti-inflammatory
cytokine. These studies showed that IL-6 can suppress the
secretion of many proinflammatory cytokines and exerts anti-
inflammatory effect both locally and systemically.53,54 In
addition, it has been shown that, when IL-6 is downregulated
in MSCs, cells lose their immune privilege by changing the
expression pattern of MHC surface antigens and triggering
cell rejection after implantation.55 The abundant secretion of
these immunomodulatory factors by hT-MSCs might be
responsible for the reduction of blood mononuclear cell
proliferation and proinflammatory cytokine secretion that
we observed in cocultures of the two cell types.
As for all MSCs with a potential use in cell-based ther-
apies, the establishment of a manufacturing process that
ensures the highest quality and safety of an hT-MSC-
derived engineered vascular graft is an important prerequi-
site for clinical applications. The safest option to obtain a
clinical-grade tissue-engineered vascular graft using hT-
MSCs would be to perform the whole manufacturing pro-
cess, from cell isolation through the production of the graft,
in GMP-compatible conditions.34 To attain GMP standards,
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one main requirement is to use animal-free products during
in vitro culture establishment and expansion of the cells, to
avoid the risk of graft rejection, immunoreactions, and in-
fections in the patient.32,33
In this study, we have established GMP-compliant culture
conditions for hT-MSCs and performed a systematic com-
parison between hT-MSCs isolated and cultured under a
standard procedure, which involves the use of xenogenic
supplements, and GMP conditions, using xeno-free re-
agents. GMP-grade recombinant enzymes and growth fac-
tors were used to replace animal-derived equivalents, while
human platelet lysate proved to be a good GMP-compliant
alternative to FBS.
Results from our work show that hT-MSCs cultured in
our optimized GMP-compliant xeno-free medium retained
the phenotypical, multipotency and immunogenicity prop-
erties observed with standard cell culture. In addition, the
hT-MSC high proliferative capacity is not lost, but rather
increased, when cells are cultured under xeno-free condi-
tions. This is an important finding, given that an extensive
ex vivo expansion is required to reach an adequate cell
number for the production of the engineered graft. Fur-
thermore, after extensive culture expansion, senescence
becomes critical. In this study, we demonstrated that hT-
MSCs cultured in the GMP-compliant system undergo se-
nescence more slowly than cells cultured under standard
condition.
Most importantly, the ability of hT-MSCs to grow and
engraft on the CorMatrix was retained in the xeno-free
system. In addition, the growth potential of hT-MSCs in
both conditions was further increased when cells were cul-
tured in a dynamic culture system provided by a bioreactor.
In fact, static culture can impair diffusion of nutrients and
O2 through the scaffold; therefore, it is important that the
graft is grown in a system that closely resembles the phys-
iological environment. The bioreactor mimics in vitro the
physical effect of blood flow and ensures that nutrients and
O2 are homogeneously diffused to the three-dimensional
tissue constructs, overcoming the limit of static cultures.
Collectively, our findings show for the first time that hT-
MSCs are a suitable candidate for the production of a tissue-
engineered cardiovascular graft. Furthermore, the optimiza-
tion of a xeno-free, GMP-compliant culture proved to be an
optimum system for the large-scale expansion of hT-MSCs
and the production of a tissue-engineered cardiovascular graft,
without compromising the quality of the cells. This study
represents an important step in preparing and scaling up hT-
MSC production for potential therapeutic use in children
with CHD. It demonstrated the feasibility of engineering
clinical-grade living autologous replacement graft using
thymus MSCs and proved the biocompatibility and efficacy
of such a graft for in vivo implantation and integration.
Longer-term preclinical studies are needed to confirm the
efficacy and safety of the engineered graft. Given the rapid
porcine growth rate, 6months to 1 year of follow-upwill enable
to determine whether the implanted graft will keep its patency
and function into an adult size pig, which closely reflects the
human growth. Once the long-term effectiveness and biosafety
of the bioengineered graft will be proved, the transition from
bench to bedside will require the establishment of a quality
control approach to ensure that the manufacturing process
(from the facilities, through the equipment, raw materials, and
personnel qualification) meets the relevant local and national
regulatory requirements.56 The establishment of a GMP-
compliant protocol for an hT-MSC-derived vascular graft by
our group ensures that the engineered tissue is produced in a
reproducible manner and meets the required specification to
deliver an absolutely safe and effective tissue-engineered
product for cardiac congenital defect repair.
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